Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Express Scripts
US Army
Cipla
Daiichi Sankyo
Merck
AstraZeneca
Federal Trade Commission

Generated: September 21, 2018

DrugPatentWatch Database Preview

Spectrum Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SPECTRUM PHARMS, and when can generic versions of SPECTRUM PHARMS drugs launch?

SPECTRUM PHARMS has five approved drugs.

There are seven US patents protecting SPECTRUM PHARMS drugs.

Summary for Spectrum Pharms
US Patents:7
Tradenames:4
Ingredients:4
NDAs:5

Drugs and US Patents for Spectrum Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spectrum Pharms FUSILEV levoleucovorin calcium SOLUTION;INTRAVENOUS 020140-002 Apr 29, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up
Spectrum Pharms BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes 6,888,027 ➤ Sign Up Y Y ➤ Sign Up
Spectrum Pharms EVOMELA melphalan hydrochloride POWDER;IV (INFUSION) 207155-001 Mar 10, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up
Spectrum Pharms EVOMELA melphalan hydrochloride POWDER;IV (INFUSION) 207155-001 Mar 10, 2016 RX Yes Yes 8,410,077 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SPECTRUM PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 10 mg/mL, 17.5 mL vial and 25 mL vial ➤ Subscribe 2011-10-26
➤ Subscribe Injection 50 mg/vial ➤ Subscribe 2017-09-08
➤ Subscribe Injection 500 mg/vial ➤ Subscribe 2018-07-03
➤ Subscribe Injection 50 mg/vial ➤ Subscribe 2013-12-19

Non-Orange Book US Patents for Spectrum Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,959,472 Process for preparing substantially pure diastereoisomers of tetrahydrofolic derivatives ➤ Sign Up
7,557,140 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
7,407,988 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
7,183,298 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Medtronic
Healthtrust
Boehringer Ingelheim
McKinsey
Teva
Colorcon
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.